RVTY: Raised full-year outlook after strong Q2, led by Diagnostics and AI-driven Life Sciences demand
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw 3% organic growth and adjusted EPS of $1.41, both above guidance, driven by strong Diagnostics and AI-related demand in Life Sciences. Full-year outlook was raised for organic growth, margins, and EPS, with robust cash flow and a pending China Immunodiagnostics divestiture.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw 3% organic growth and adjusted EPS of $1.41, both above guidance, driven by strong Diagnostics and AI-related demand in Life Sciences. Full-year outlook was raised for organic growth, margins, and EPS, with robust cash flow and a pending China Immunodiagnostics divestiture.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.